Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Amgen Inc.NASDAQ: AMGN

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to 35.0%

Operating margin was 35.0% in Q2 FY2026, up 6.1 pp from a year earlier. On a trailing-twelve-month basis it was 33.2%, up 9.7 pp year over year. Over 3 fiscal years it narrowed by 7.3 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 22 analysts of 44.5% for the fiscal year ending Dec 2026, up from 29.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
35.0%+4.0 pp QoQ
Last fiscal yearDec 2025
29.1%+7.3 pp YoY
LTMJun 2026
33.2%+9.7 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.1 pp+15.9 pp+9.8 pp
1 year+7.3 pp+15.4 pp+8.1 pp
3 years-7.3 pp+16.0 pp+23.3 pp
5 years+17.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.1%
Year-over-year change
+7.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How AMGN compares with its peers on the latest reported figures

  • AMGN's LTM Jun 2026 operating margin of 33.2% is the 3rd highest of the 10 companies compared; the peer median is 26.7%.
  • Its year-over-year change of +9.7 pp is the 2nd highest of 10, against a peer median of +1.6 pp.
  • Over three fiscal years its change of -7.3 pp compares with a peer median of +5.3 pp.
AMGN Competitors Peer median
Operating Margin for AMGN and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202649.7% +7.6 pp+15.2 pp
ABBVAbbVie Inc.LTM Sep 202635.5% +20.4 pp+1.6 pp
AMGNAmgen Inc.LTM Jun 202633.2% +9.7 pp-7.3 pp
NVSNovartis AGLTM Jun 202630.5% +0.3 pp+12.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202628.1% +7.3 pp+8.8 pp
PFEPfizer Inc.LTM Jun 202626.7% +0.6 pp-9.9 pp
JNJJohnson & JohnsonLTM Sep 202625.7% -0.4 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
GSKGSK plcLTM Jun 202620.7% +4.5 pp+3.6 pp
MRKMerck & Co., Inc.LTM Jun 202616.7% -16.9 pp+5.3 pp
Peer median (excluding AMGN) 26.7%+1.6 pp+5.3 pp

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.